Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Fully human antibody More
This invention proposes methods to predict an individual's genetic susceptibility to venous thrombosis. More
Use of substituted or modified C60 fullerenes for the prevention or treatment of thrombosis, peripheral arterial occlusion, and catheter obstruction. More
Direct thrombin inhibitors designed for improved safety/efficacy profile. Peptide inhibitors suitable for cost-effective recombinant production.Anti-thrombin peptides that can be fused to homing peptides for targeted delivery or fused to markers. More
Gene-therapy product combining pCK naked DNA vector with genetically engineered Hepatocyte Growth Factor gene More
A new route to tissue and blood compatible medical devices More
Retractable inhibitors controlled through polypeptide-protein interactions with the flexible peptide bridge that link the two binding fragments may represent an alternative approach to antidote-reversible anticoagulant therapy. More
Compositions and methods of treating tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Arterial occlusive disorder
- Peripheral arterial disease
- Peripheral vascular disease
- Platelet aggregation
- Pulmonary embolism
- Thrombosis
- Thrombosis, deep vein
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us